
CLAIMS

1. Use of a pharmaceutical composition comprising a compound of formula (I) or the pharmaceutically acceptable salt thereof and a cyclodextrin in the manufacture of a medicament for use in a method of safely administering the compound of formula (I)




(I)

or a pharmaceutically acceptable salt thereof, to a human subject in need thereof, wherein the pharmaceutical composition comprising the compound of formula (I) or the pharmaceutically acceptable salt thereof and a cyclodextrin is to be administered orally, and wherein a total dosage of the compound of formula (I) or the pharmaceutically acceptable salt thereof to be administered is about 25 mg to about 600 mg per administration.

2. The use of claim 1, wherein the total dosage of the compound of formula (I) or the pharmaceutically acceptable salt thereof to be administered per administration is about 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or 600 mg, or any dosage in between.

3. The use of claim 1 or 2, wherein the pharmaceutical composition is to be orally administered once per day or twice per day.

4. Use of a pharmaceutical composition comprising a cyclodextrin and a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease in a human subject in need thereof, wherein a total dosage

of the compound of formula (I) or the pharmaceutically acceptable salt thereof to be administered is about 25 mg to about 600 mg per administration, and the disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis.

5. The use of claim 4, wherein the total dosage of the compound of formula (I) or the pharmaceutically acceptable salt thereof to be administered per administration is about 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or 600 mg, or any dosage in between.

6. The use of claim 5 or 6, wherein the pharmaceutical composition is to be orally administered once per day or twice per day.

7. The use of any one of claims 4 to 6, wherein the pharmaceutical composition is to be orally administered twice per day, and the total dosage of the compound of formula (I) or the pharmaceutically acceptable salt thereof to be administered per administration is about 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or 600 mg, or any dosage in between.

8. The use of any one of claims 4 to 6, wherein the pharmaceutical composition is to be orally administered twice per day, and the total dosage of the compound of formula (I) or the pharmaceutically acceptable salt thereof to be administered per day is about 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1100 mg, or 1200 mg, or any dosage in between.

9. The use of any one of claims 1 to 8, wherein the composition comprises the compound of formula (I).

10. The use of claim 9, wherein the compound of formula (I) is amorphous.

11. The method of any one of claims 1 to 10, wherein the cyclodextrin is a hydroxypropyl beta-cyclodextrin (HPBCD).

12. The method of any one of claims 1 to 11, wherein a weight ratio of the compound of formula (I) to the cyclodextrin is from 1:1 to 1:10.